What 4 Analyst Ratings Have To Say About CareDx
Portfolio Pulse from Benzinga Insights
In the last three months, four analysts have rated CareDx (NASDAQ:CDNA) with a bullish outlook. The average 12-month price target has increased by 64.45% to $28.5. Analysts from BTIG, Goldman Sachs, and Craig-Hallum have raised their price targets, reflecting positive sentiment. CareDx, a precision medicine company, has shown a 31.26% revenue growth rate, though it remains below industry averages. The company's financial health is strong, with efficient cost management and a sound debt structure.
August 19, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CareDx has received bullish ratings from four analysts, with an average price target increase of 64.45% to $28.5. Analysts from BTIG, Goldman Sachs, and Craig-Hallum have raised their price targets, indicating positive sentiment. The company has shown a 31.26% revenue growth rate, though it remains below industry averages. CareDx's financial health is strong, with efficient cost management and a sound debt structure.
The bullish ratings from multiple analysts and the significant increase in the average price target suggest a positive short-term impact on CareDx's stock price. The company's strong financial health and revenue growth, despite being below industry averages, further support this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100